Related Experiment Videos
Current status of oxaliplatin in colorectal cancer
Peter J O'Dwyer1, Steven W Johnson
1University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.
Abstract:
Novel platinum compounds have been sought with the goal of identifying molecules active in cisplatin-resistant cancers such as colorectal cancer. Some 30 years ago it was shown that varying the structure of the coordination complex could enhance the activity of platinum compounds against preclinical models. The diaminocyclohexane ligand, now embodied in the structure of oxaliplatin, was the most promising of a series of such analogues. Oxaliplatin has recently been approved in the United States for the treatment of refractory colorectal cancer. Studies in the initial treatment of advanced disease indicate that its activity when used in combination with 5-fluorouracil (5-FU) is at least as good as standard therapy for this stage of the disease. Novel combinations have been reported in phase II studies, and adjuvant trials have been completed in the United States and Europe. It is reasonable to conclude that there are now two accepted regimens for the treatment of colorectal cancer, irinotecan/5-FU and oxaliplatin/5-FU. Early studies using both regimens sequentially are of interest, and phase I trials of three-drug combinations have been presented. Current efforts are directed toward individualizing therapy through predictive analyses of the targets and metabolic pathways of all three agents in pharmacogenetic and pharmacogenomic studies.
Insights
Novel platinum compounds like oxaliplatin show promise for treating cisplatin-resistant colorectal cancer. Current research focuses on optimizing combination therapies and individualizing treatment through pharmacogenomic studies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Cisplatin resistance is a significant challenge in colorectal cancer treatment.
- Structural modifications of platinum compounds can enhance anti-cancer activity.
- Oxaliplatin, a novel platinum compound, targets cisplatin-resistant cancers.
Purpose of the Study:
- To evaluate the efficacy of oxaliplatin in cisplatin-resistant colorectal cancer.
- To explore novel combination therapies involving oxaliplatin and 5-fluorouracil (5-FU).
- To investigate strategies for individualizing colorectal cancer treatment through pharmacogenetics.
Main Methods:
- Review of preclinical and clinical studies on oxaliplatin and its analogues.
- Analysis of data from phase II and adjuvant trials of oxaliplatin-based regimens.
- Exploration of pharmacogenomic and pharmacogenetic approaches for treatment individualization.
Main Results:
- Oxaliplatin is approved for refractory colorectal cancer treatment.
- Oxaliplatin in combination with 5-FU demonstrates efficacy comparable to standard therapy for advanced colorectal cancer.
- Two accepted treatment regimens for colorectal cancer are irinotecan/5-FU and oxaliplatin/5-FU.
Conclusions:
- Oxaliplatin represents a significant advancement in colorectal cancer therapy, particularly for resistant cases.
- Combination therapies and sequential use of irinotecan/5-FU and oxaliplatin/5-FU are established treatment options.
- Future directions include personalized medicine approaches using pharmacogenomic data to optimize treatment strategies.